ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 9, 2010, Pages 2133-2142

  Kauppinen, Jaana M ^a   Kosma, Veli Matti ^a   Soini, Ylermi ^a   Sironen, Reijo ^a   Nissinen, Minna ^a   Nykopp, Timo K ^a   Kärjä, Vesa ^a   Eskelinen, Matti ^b   Kataja, Vesa ^b,c   Mannermaa, Arto ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR; GENOMIC DNA; MATRIPTASE;

ALLELE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DNA EXTRACTION; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; RNA EXTRACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY; TUMOR BIOPSY; TUMOR VOLUME;

ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SERINE ENDOPEPTIDASES; SURVIVAL RATE;

EID: 77956520950     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0418     Document Type: Article

References (49)

1. Lin CY, Wang JK, Torri J, Dou L, Sang QA, Dickson RB. Characterization of a novel membrane-bound, 80-kDA matrix-degrading protease from human breast cancer cells. J Biol Chem 1997;272:9147-52.
2. Zhang Y, Cai X, Schlegelberger B, Zheng S. Assignment of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24→q25 by in situ hybridization. Cytogenet Cell Genet 1998;83:56-7. (Pubitemid 29062687)
3. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999;274:18231-6. (Pubitemid 129519220)
4. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A 1999;96:11054-61. (Pubitemid 29487326)
5. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 2001;22:104-14. (Pubitemid 32008967)
6. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001;276:857-60.
7. Netzel-Arnett S, Hooper JD, Szabo R, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 2003;22:237-58. (Pubitemid 36561060)
8. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinasetype plasminogen activator as substrates. J Biol Chem 2000;275:26333-42.
9. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000;275:36720-5.
10. Bhatt AS, Welm A, Faraday CJ, Vasquez M, Wilson K, Craik CS. Coordinate expression and functional profiling identify an extracellular proteolytic signalling pathway. PNAS 2007;104:5771-6. (Pubitemid 47175609)
11. Jin X, Yagi M, Akiyama N, et al. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 2006;97:1327-34. (Pubitemid 44614984)
12. Ahmed S, Jin X, Yagi M, et al. Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). FEBS J 2006;273:615-27.
13. Szabo R, Molinolo A, List K, Bugge TH. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene 2007;26:1546-56. (Pubitemid 46398747)
14. Carney TJ, von der Hardt S, Sonntag C, et al. Inactivation of serine protease Matriptase1a by its inhibitor Hai1 is required for epithelial integrity of the zebrafish epidermis. Development 2007;134:3461-71. (Pubitemid 350028365)
15. List K, Kosa P, Szabo R, et al. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 2009;175:1453-63.
16. Lee SL, Huang PY, Roller P, Cho EG, Park D, Dickson RB. Matriptase/ epithin participates in mammary epithelial cell growth and morphogenesis through HGF activation. Mech Develop 2010;127:82-95, Epub 2009 Oct 22.
17. List K, Szabo R, Molinolo A, et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 2005;19:1934-50. (Pubitemid 41186993)
18. Shimomura T, Denda K, Kitamura A, et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997;272:6370-6. (Pubitemid 27118113)
19. Itoh H, Yamauchi M, Kataoka H, Hamasuna R, Kitamura N, Koono M. Genomic structure and chromosomal localization of the human hepatocyte growth factor activator inhibitor type 1 and 2 genes. Eur J Biochem 2000;267:3351-9. (Pubitemid 30341165)
20. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999;274:18237-42. (Pubitemid 129519221)
21. Benaud CM, Oberst M, Dickson RB, Lin CY. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 2002;19:639-49. (Pubitemid 35454575)
22. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 2003;278:26773-9.
23. Benaud C, Dickson RB, Lin CY. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem 2001;268:1439-47. (Pubitemid 32231898)
24. Lee MS, Kiyomiya K, Benaud C, Dickson RB, Lin CY. Simultaneous activation and heptocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. Am J Physiol Cell Physiol 2005;288:C932-41. (Pubitemid 40395072)
25. Oberst MD, Chen LYL, Kiyomiya KI, et al. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol 2005;289:C462-70.
26. Oberst MD, Anders J, Xie B, et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001;158:1301-11.
27. Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY. Characterization of matriptase expression in normal human tissues. J Histochem Cytochem 2003;51:1017-25. (Pubitemid 36919979)
28. Kataoka H, Suganuma T, Shimomura T, et al. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues: cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem 1999;47:673-82. (Pubitemid 29237303)
29. Wang JK, Lee MS, Tseng IC, et al. Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1 mediated inhibition. Am J Physiol Cell Physiol 2009;297:459-70.
30. Oberst MD, Johnson MD, Dickson RB, et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002;8:1101-7.
31. Kang JY, Dolled-Filhart M, Tolgay Ocal I, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003;63:1101-5. (Pubitemid 36278444)
32. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004;10:202-11. (Pubitemid 38114181)
33. Welm AL, Sneddon JB, Taylor C, et al. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A 2007;104:7570-5.
34. Tsai WC, Chu CH, Yu CP, et al. Matriptase and surviving expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 2008;24:89-99.
35. Basel-Vanagaite L, Attia R, Ishida-Yamamoto A, et al. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am J Hum Genet 2007;80:467-77.
36. Désilets A, Béliveau F, Vandal G, McDuff FO, Lavigne P, Leduc R. Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease. J Biol Chem 2008;283:10535-42.
37. Hartikainen JM, Tuhkanen H, Kataja V, et al. An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in Eastern Finland: three candidate regions found. Cancer Epidemiol Biomarkers Prev 2005;14:75-80.
38. Hartikainen JM, Tuhkanen H, Kataja V, et al. Refinement of the 22q12-q13 breast cancer-associated region: evidence of TMPRSS6 as a candidate gene in an Eastern Finnish population. Clin Cancer Res 2006;12:1454-62.
39. Velasco G, Cal S, Quesada V, Sanchez LM, Lopez-Otin C. Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 2002;277:37637-46.
40. Pellikainen MJ, Pekola TT, Ropponen KM, et al. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 2003;56:214-20.
41. Vandenplas S, Wiid J, Grobler-Rabie A, et al. Blot hybridisation analysis of genomic DNA. J Med Genet 1984;21:164-72.
42. Nykopp TK, Rilla K, Sironen R, et al. Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: Inverse correlation between HYAL1 and hyaluronan content. BMC Cancer 2009;9:143.
43. HapMap [Internet]. International HapMap Project. HapMap Data PhaseIII/rel#2, Feb09, NCBI B36 assembly, dbSNP b126 - [cited 2009 Dec 16]. Available from: http://hapmap.ncbi.nlm.nih.gov/cgiperl/gbrowse/hapmap3r2-B36/ #search.
44. dbSNP [Internet]. NCBI Entrez Single Nucleotide Polymorphism. [cited 2009 Dec 16]. Available from: http://www.ncbi.nlm.nih.gov/SNP.
45. de Kok JB, Roelofs RW, Giesendorf BA, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 2005;85:154-9.
46. Voutilainen K, Anttila M, Sillanpää S, et al. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 2003;107:359-64.
47. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLOS Med 2008;5:e232.
48. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995;29:311-22.
49. Tanimoto H, Shigemasa K, Tian X, et al. Transmembrane serine protease TADG-15 (ST14/matriptase/MT-SP1): expression and prognostic value in ovarian cancer. Br J Cancer 2005;92:278-83.